By Philips ∙ jūn. 12, 2017 ∙ 2 min read
iFR is the global gold standard among resting indices, with a Class IA recommendation in the ACC/AHA/SCAI and ESC Guidelines.1,3 This is backed by clinical evidence and patient outcomes showing reduced costs, procedural time and patient discomfort.2 iFR also provides advanced guidance with iFR pullback and co-registration for PCI planning throughout the entire case. Learn more about the latest iFR patient studies and view the latest 5-year outcomes update.
Unseen focal lesions cause residual ischemia. The DEFINE PCI study used iFR pullback to understand the rate and causes of residual ischemia in 500 patients undergoing contemporary PCI. Early results find that residual ischemia is common, and causes are treatable.3,4
DEFINE Flair and iFR Swedeheart are 2 prospective randomized controlled studies published in the prestigious New England Journal of Medicine and combined represent the largest physiology clinical dataset with more than 4500 patients. Learn more DEFINE FLAIR, iFR Swedeheart.
* p-values are for non-inferiority of an iFR-guided strategy versus an FFR-guided strategy with respect to 1-year MACE rates; pre-specified non-inferiority margins were 3.4% and 3.2% in DEFINE FLAIR and iFR Swedeheart, respectively.
** MACE rates at 5-years: 21.5% iFR vs. 19.9% FFR (HR 1.09; 95% CI: 0.90, 1.33)
Reduced costs per patient DEFINE FLAIR and iFR Swedeheart found that on average, compared to FFR, iFR resulted in: Less procedural time DEFINE FLAIR found that an iFR-guided strategy resulted in: Improved care The two trials further established that an iFR-guided strategy enables a faster procedure while almost completely eliminating severe patient symptoms compared to an FFR-guided strategy.
1. Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129.
.2. Gotberg M, et al. Instantaneous wave-free ratio compared with fractional flow reserve in PCI: A cost-minimization analysis. Int J Cardiol 2021 1;344:54-59.
3. 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96. Japan guidelines
4. Jeremias A et al. Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019 Oct 28;12(20):1991-2001.
5. Patel M., et al. 1-Year outcomes of blinded physiological assessment of residual ischemia after successful PCI. JACC Cardiol Interv. 2022;15(1):52-61.
6. FDA 510k (#K173860). The iFR modality is intended to be used in conjunction with currently marketed Philips pressure wires. In the coronary anatomy, the iFR modality has a diagnostic cut-point of 0.89 which represents an ischemic threshold and can reliably guide revascularization decisions during diagnostic catheterization procedure.
7. Gotberg M. et al. iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI. Late-breaking clinical Trial presentation at TCT on November 4, 2021.
8. Gotberg et al. The Evolving Future of Instantaneous Wave-Free Ratio and Fractional Flow Reserve. State of the Art.
Always read the label and follow the directions for use.Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device.
Products subject to country availability. Please contact your local sales representative.
©2024 Koniklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners. Philips reserves the right to change product specifications without prior notification.
You are about to visit a Philips global content page
ContinueTīmekļa vietne ir paredzēta tikai personām, kuras izmanto medicīniskās ierīces kā profesionāļi, tostarp personām, kas praktizē medicīnas profesijās, personām, kas darbojas veselības aprūpes iestāžu labā vai organizācijām, kas tirgo medicīnas ierīces kā profesionāļi.
Vai esat persona, kas atbilst iepriekš minētajiem kritērijiem?